- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05310838
Optimizing Engagement in Services for First-Episode Psychosis
March 16, 2026 updated by: Maria Santos, California State University, San Bernardino
Optimizing Engagement in Services for First-Episode Psychosis (FEP) in the Community Mental Health Setting
This study will compare a 12-session behavioral activation (BA) intervention modified for first-episode psychosis (FEP) to usual community mental health care (i.e., treatment-as-usual; TAU) delivered over 6 months with a sample of Latinos with FEP and their families.
Comparable family group sessions will also be delivered to participants in both conditions.
It is expected that BA participants will show better engagement than TAU participants.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
After an initial pre-screen, screening, and pre-intervention assessment, enrolled participants will be randomized to either BA or TAU.
The study intervention phase will last up to 6 months, during which time BA participants will receive up to 12 one-on-one BA sessions and TAU participants will receive the usual care (e.g., medication management and any other service [e.g., group counseling]).
Participants will be assessed at post-intervention, 1-month-post-intervention, and 6-month-post-intervention. The primary objective of aim 1 is to examine whether BA for FEP improves engagement in services better than TAU among Latinos with FEP and their families.
Secondary objectives of aim 1 are to examine whether BA participants show greater improvements in quality of life, symptoms (e.g., psychosis, depression), functioning, and recovery compared to TAU participants, and whether BA participants have greater remission rates than the TAU group at 1- and 6-month post-intervention.
Additionally, the association between potential BA mediators and engagement will be examined to identify mechanisms of engagement.
Potential predictors of engagement will also be examined.
Study Type
Interventional
Enrollment (Estimated)
58
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Granada Hills, California, United States, 91344
- San Fernando Mental Health Center
-
Sylmar, California, United States, 91342
- Olive View - UCLA Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years to 35 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Self-identification as Latino
- Age 15 to 35
- Diagnostic & Statistical Manual of Mental Disorders-5 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, other specified schizophrenia spectrum, affective psychosis, and other psychotic disorder criteria
- Ability to speak English or Spanish
- Caregiver willing to consent to participate in the study and care
- Ability to provide fully informed consent
Exclusion Criteria:
- Diagnosis of psychotic disorder due to another medical condition or substance/medication-induced psychotic disorder
- Presence of a serious medical condition
- 3≤ years after the onset
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Behavioral Activation for First Episode Psychosis
Patients will receive BA for FEP in individual session format provided by the PI based on a manual adapted for this study.
|
Sessions will be offered weekly and dyads can complete the intervention during a 6-month period to accommodate competing demands encountered by the population.
|
|
Active Comparator: Treatment at Usual
Patients randomized to TAU will receive typical clinic care offered beyond psychiatric services.
|
Given this condition, patients may also receive individual rehabilitation and/or group psychosocial interventions as part of typical clinic care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Engagement on the Patient Activation Measure (PAM13) at Post-Intervention
Time Frame: Change from Pre-intervention PAM13 at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
PAM13 is a 13-item self-report short form of a patient's engagement in the care process at four stages.
PAM13 shows high reliability that is stable across chronic illnesses and high construct validity, and measures change over time.
Items are rated on a 4-point Likert scale (totally disagree to totally agree) with higher scores reflecting higher activation; respondent may select 'not applicable.'
|
Change from Pre-intervention PAM13 at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
Change in Engagement on the Patient Activation Measure (PAM13) at 1-Month Post-Intervention
Time Frame: Change from Pre-intervention PAM13 at 1-month-post-intervention
|
PAM13 is a 13-item self-report short form of a patient's engagement in the care process at four stages.
PAM13 shows high reliability that is stable across chronic illnesses and high construct validity, and measures change over time.
Items are rated on a 4-point Likert scale (totally disagree to totally agree) with higher scores reflecting higher activation; respondent may select 'not applicable.'
|
Change from Pre-intervention PAM13 at 1-month-post-intervention
|
|
Change in Engagement on the Patient Activation Measure (PAM13) at 6-Months Post-Intervention
Time Frame: Change from Pre-intervention PAM13 at 6-months-post-intervention
|
PAM13 is a 13-item self-report short form of a patient's engagement in the care process at four stages.
PAM13 shows high reliability that is stable across chronic illnesses and high construct validity, and measures change over time.
Items are rated on a 4-point Likert scale (totally disagree to totally agree) with higher scores reflecting higher activation; respondent may select 'not applicable.'
|
Change from Pre-intervention PAM13 at 6-months-post-intervention
|
|
Engagement as measured by the Service Engagement Scale (SES)
Time Frame: Weekly per session up to 12 sessions, up to 6 months
|
The 14-item provider rated SES has demonstrated good reliability and validity and reflects client availability, collaboration, help-seeking, and adherence.
Items are rated on a 4-point Likert scale with higher scores reflecting clients' greater levels of difficulty engaging with services.
The SES is a secondary measure of service engagement.
|
Weekly per session up to 12 sessions, up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Quality of Life on the Heinrichs-Carpenter Quality of Life Scale (QLS) at Post-Intervention
Time Frame: Change from Pre-intervention QLS at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
The QLS is a 21-item, clinician-administered, semi-structured interview on a 7-point scale with higher scores reflecting normal or unimpaired functioning.
It has shown high sensitivity to change and treatment effect.
The total score is the main secondary outcome of interest.
|
Change from Pre-intervention QLS at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
Change in Quality of Life on the Heinrichs-Carpenter Quality of Life Scale (QLS) at 1-Month Post-Intervention
Time Frame: Change from Pre-intervention QLS at 1-month-post-intervention
|
The QLS is a 21-item, clinician-administered, semi-structured interview on a 7-point scale with higher scores reflecting normal or unimpaired functioning.
It has shown high sensitivity to change and treatment effect.
The total score is the main secondary outcome of interest.
|
Change from Pre-intervention QLS at 1-month-post-intervention
|
|
Change in Quality of Life on the Heinrichs-Carpenter Quality of Life Scale (QLS) at 6-Months Post-Intervention
Time Frame: Change from Pre-intervention QLS at 6-months-post-intervention
|
The QLS is a 21-item, clinician-administered, semi-structured interview on a 7-point scale with higher scores reflecting normal or unimpaired functioning.
It has shown high sensitivity to change and treatment effect.
The total score is the main secondary outcome of interest.
|
Change from Pre-intervention QLS at 6-months-post-intervention
|
|
Change in Quality of Life on the Modified Lehman Quality of Life Inventory (QOLI-M) at Post-Intervention
Time Frame: Change from Pre-intervention QOLI-M at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
The QOLI-M has well established psychometric properties with individuals with serious mental illness (SMI) and will be used to derive overall subjective quality of life and objective and subjective quality of social and family interaction ratings.
The QOLI-M, not the QLS, assesses general quality of life which focuses on areas beyond those affected by psychotic illness.
|
Change from Pre-intervention QOLI-M at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
Change in Quality of Life on the Modified Lehman Quality of Life Inventory (QOLI-M) at 1-Month Post-Intervention
Time Frame: Change from Pre-intervention QOLI-M at 1-month-post-intervention
|
The QOLI-M has well established psychometric properties with individuals with serious mental illness (SMI) and will be used to derive overall subjective quality of life and objective and subjective quality of social and family interaction ratings.
The QOLI-M, not the QLS, assesses general quality of life which focuses on areas beyond those affected by psychotic illness.
|
Change from Pre-intervention QOLI-M at 1-month-post-intervention
|
|
Change in Quality of Life on the Modified Lehman Quality of Life Inventory (QOLI-M) at 6-Months Post-Intervention
Time Frame: Change from Pre-intervention QOLI-M at at 6-months-post-intervention
|
The QOLI-M has well established psychometric properties with individuals with serious mental illness (SMI) and will be used to derive overall subjective quality of life and objective and subjective quality of social and family interaction ratings.
The QOLI-M, not the QLS, assesses general quality of life which focuses on areas beyond those affected by psychotic illness.
|
Change from Pre-intervention QOLI-M at at 6-months-post-intervention
|
|
Change in Symptoms on the Positive And Negative Syndrome Scale (PANSS) at Post-Intervention
Time Frame: Change from Pre-intervention PANSS at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
This 30-item widely-used clinician-administered instrument measures psychosis symptom severity and remission.
Scores 4 ≤ on delusions, conceptual disorganization, hallucinatory behavior, mannerisms & posturing, and unusual thought content will be considered in remission.
|
Change from Pre-intervention PANSS at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
Change in Symptoms on the Positive And Negative Syndrome Scale (PANSS) at 1-Month Post-Intervention
Time Frame: Change from Pre-intervention PANSS at 1-month-post-intervention
|
This 30-item widely-used clinician-administered instrument measures psychosis symptom severity and remission.
Scores 4 ≤ on delusions, conceptual disorganization, hallucinatory behavior, mannerisms & posturing, and unusual thought content will be considered in remission.
|
Change from Pre-intervention PANSS at 1-month-post-intervention
|
|
Change in Symptoms on the Positive And Negative Syndrome Scale (PANSS) at 6-Months Post-Intervention
Time Frame: Change from Pre-intervention PANSS at 6-months-post-intervention
|
This 30-item widely-used clinician-administered instrument measures psychosis symptom severity and remission.
Scores 4 ≤ on delusions, conceptual disorganization, hallucinatory behavior, mannerisms & posturing, and unusual thought content will be considered in remission.
|
Change from Pre-intervention PANSS at 6-months-post-intervention
|
|
Change in Functioning on the Strauss-Carpenter level of Function Scale (Strauss-Carpenter) at Post-Intervention
Time Frame: Change from Pre-intervention Strauss-Carpenter at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
The Strauss-Carpenter is a semi-structured interviewer-administered scale that assesses functioning in social contacts, work, symptomatology, and function.
Items are rated on a five-point scale (0-4) with higher scores reflecting better functioning.
|
Change from Pre-intervention Strauss-Carpenter at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
Change in Functioning on the Strauss-Carpenter level of Function Scale (Strauss-Carpenter) at 1-Month Post-Intervention
Time Frame: Change from Pre-intervention Strauss-Carpenter at 1-month-post-intervention
|
The Strauss-Carpenter is a semi-structured interviewer-administered scale that assesses functioning in social contacts, work, symptomatology, and function.
Items are rated on a five-point scale (0-4) with higher scores reflecting better functioning.
|
Change from Pre-intervention Strauss-Carpenter at 1-month-post-intervention
|
|
Change in Functioning on the Strauss-Carpenter level of Function Scale (Strauss-Carpenter) at 6-Months Post-Intervention
Time Frame: Change from Pre-intervention Strauss-Carpenter at 6-months-post-intervention
|
The Strauss-Carpenter is a semi-structured interviewer-administered scale that assesses functioning in social contacts, work, symptomatology, and function.
Items are rated on a five-point scale (0-4) with higher scores reflecting better functioning.
|
Change from Pre-intervention Strauss-Carpenter at 6-months-post-intervention
|
|
Change in Depression on the Calgary Depression Scale (CDS) at Post-Intervention
Time Frame: Change from Pre-intervention CDS at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
The CDS is an interview-based 9-item scale that measures depression severity in people with schizophrenia and is valid and reliable.
Items are rated on a four-point scale with higher scores reflecting greater severity of symptoms.
|
Change from Pre-intervention CDS at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
Change in Depression on the Calgary Depression Scale (CDS) at 1-Month Post-Intervention
Time Frame: Change from Pre-intervention CDS at 1-month-post-intervention
|
The CDS is an interview-based 9-item scale that measures depression severity in people with schizophrenia and is valid and reliable.
Items are rated on a four-point scale with higher scores reflecting greater severity of symptoms.
|
Change from Pre-intervention CDS at 1-month-post-intervention
|
|
Change in Depression on the Calgary Depression Scale (CDS) at 6-Months Post-Intervention
Time Frame: Change from Pre-intervention CDS at 6-months-post-intervention
|
The CDS is an interview-based 9-item scale that measures depression severity in people with schizophrenia and is valid and reliable.
Items are rated on a four-point scale with higher scores reflecting greater severity of symptoms.
|
Change from Pre-intervention CDS at 6-months-post-intervention
|
|
Change in Recovery as measured by the Maryland Assessment of Recovery in People with SMI (MARS) at Post-Intervention
Time Frame: Change from Pre-intervention MARS at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
The 25-item patient-report MARS measures recovery and has excellent internal consistency and test-retest reliability and good face and content validity.
Items are rated on a five-point scale with higher scores reflecting greater self-reported recovery.
|
Change from Pre-intervention MARS at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
Change in Recovery as measured by the Maryland Assessment of Recovery in People with SMI (MARS) at 1-Month Post-Intervention
Time Frame: Change from Pre-intervention MARS at 1-month-post-intervention
|
The 25-item patient-report MARS measures recovery and has excellent internal consistency and test-retest reliability and good face and content validity.
Items are rated on a five-point scale with higher scores reflecting greater self-reported recovery.
|
Change from Pre-intervention MARS at 1-month-post-intervention
|
|
Change in Recovery as measured by the Maryland Assessment of Recovery in People with SMI (MARS) at 6-Months Post-Intervention
Time Frame: Change from Pre-intervention MARS at 6-months-post-intervention
|
The 25-item patient-report MARS measures recovery and has excellent internal consistency and test-retest reliability and good face and content validity.
Items are rated on a five-point scale with higher scores reflecting greater self-reported recovery.
|
Change from Pre-intervention MARS at 6-months-post-intervention
|
|
PANSS-based Remission Rates at Post-Intervention
Time Frame: Remission at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
Scores 4 ≤ on delusions, conceptual disorganization, hallucinatory behavior, mannerisms & posturing, and unusual thought content will be considered in remission.
|
Remission at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
PANSS-based Remission Rates at 1-Month Post-Intervention
Time Frame: Remission at 1-month-post-intervention
|
Scores 4 ≤ on delusions, conceptual disorganization, hallucinatory behavior, mannerisms & posturing, and unusual thought content will be considered in remission.
|
Remission at 1-month-post-intervention
|
|
PANSS-based Remission Rates at 6-Months Post-Intervention
Time Frame: Remission at 6-months-post-intervention
|
Scores 4 ≤ on delusions, conceptual disorganization, hallucinatory behavior, mannerisms & posturing, and unusual thought content will be considered in remission.
|
Remission at 6-months-post-intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Activation as measured by the Behavioral Activation for Depression Scale-Short Form (BADS-SF) at Post-Intervention
Time Frame: Change from Pre-intervention BADS-SF at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
The 9-item self-report BADS-SF tracks when and how changes in activation occur (7-point scale; not at all to completely).
It has shown good internal consistency reliability, construct validity, and predictive validity.
BADS-SF is the primary measure of activation.
|
Change from Pre-intervention BADS-SF at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
Change in Activation as measured by the Behavioral Activation for Depression Scale-Short Form (BADS-SF) at 1-Month Post-Intervention
Time Frame: Change from Pre-intervention BADS-SF at 1-month-post-intervention
|
The 9-item self-report BADS-SF tracks when and how changes in activation occur (7-point scale; not at all to completely).
It has shown good internal consistency reliability, construct validity, and predictive validity.
BADS-SF is the primary measure of activation.
|
Change from Pre-intervention BADS-SF at 1-month-post-intervention
|
|
Change in Activation as measured by the Behavioral Activation for Depression Scale-Short Form (BADS-SF) at 6-Months Post-Intervention
Time Frame: Change from Pre-intervention BADS-SF at 6-months-post-intervention
|
The 9-item self-report BADS-SF tracks when and how changes in activation occur (7-point scale; not at all to completely).
It has shown good internal consistency reliability, construct validity, and predictive validity.
BADS-SF is the primary measure of activation.
|
Change from Pre-intervention BADS-SF at 6-months-post-intervention
|
|
Activation as measured by the Behavioral Activation Homework Completion Observer-Based Coding System (BA HC)
Time Frame: Weekly per session up to 12 sessions, up to 6 months
|
BA HC permits reliable coding of the characterization and completion of BA homework, including type of assignment, realm of functioning it targets, and the extent of homework completion.
It will be used as a secondary measure of activation for BA.
|
Weekly per session up to 12 sessions, up to 6 months
|
|
Change in Environmental Reward as measured by the Reward Probability Index (RPI) at Post-Intervention
Time Frame: Change from Pre-intervention RPI at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
RPI is a 20-item self-report measure of contact with environmental reward, which is theorized to maintain healthy behavior per behavioral models of psychopathology, with good internal consistency, test-retest reliability, and discriminant, predictive, and convergent validity.
Items are rated on a 4-point Likert scale with higher scores indicating higher levels of reinforcement.
|
Change from Pre-intervention RPI at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
Change in Environmental Reward as measured by the Reward Probability Index (RPI) at 1-Month Post-Intervention
Time Frame: Change from Pre-intervention RPI at 1-month-post-intervention
|
RPI is a 20-item self-report measure of contact with environmental reward, which is theorized to maintain healthy behavior per behavioral models of psychopathology, with good internal consistency, test-retest reliability, and discriminant, predictive, and convergent validity.
Items are rated on a 4-point Likert scale with higher scores indicating higher levels of reinforcement.
|
Change from Pre-intervention RPI at 1-month-post-intervention
|
|
Change in Environmental Reward as measured by the Reward Probability Index (RPI) at 6-Months Post-Intervention
Time Frame: Change from Pre-intervention RPI at 6-months-post-intervention
|
RPI is a 20-item self-report measure of contact with environmental reward, which is theorized to maintain healthy behavior per behavioral models of psychopathology, with good internal consistency, test-retest reliability, and discriminant, predictive, and convergent validity.
Items are rated on a 4-point Likert scale with higher scores indicating higher levels of reinforcement.
|
Change from Pre-intervention RPI at 6-months-post-intervention
|
|
Change in medication adherence as measured by the Brief Adherence Rating Scale (BARS) at Post-Intervention
Time Frame: Change from Pre-intervention BARS at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
The 4-item BARS is a brief, clinician-administered instrument to assess oral antipsychotic medication adherence and has good sensitivity (73%) and specificity (74%) in identifying non-adherent outpatients (defined as <70% mean electronic monitoring adherence).
|
Change from Pre-intervention BARS at Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
Change in medication adherence as measured by the Brief Adherence Rating Scale (BARS) at 1-Month Post-Intervention
Time Frame: Change from Pre-intervention BARS at 1-month-post-intervention
|
The 4-item BARS is a brief, clinician-administered instrument to assess oral antipsychotic medication adherence and has good sensitivity (73%) and specificity (74%) in identifying non-adherent outpatients (defined as <70% mean electronic monitoring adherence).
|
Change from Pre-intervention BARS at 1-month-post-intervention
|
|
Change in medication adherence as measured by the Brief Adherence Rating Scale (BARS) at 6-Months Post-Intervention
Time Frame: Change from Pre-intervention BARS at 6-months-post-intervention
|
The 4-item BARS is a brief, clinician-administered instrument to assess oral antipsychotic medication adherence and has good sensitivity (73%) and specificity (74%) in identifying non-adherent outpatients (defined as <70% mean electronic monitoring adherence).
|
Change from Pre-intervention BARS at 6-months-post-intervention
|
|
Alliance as measured by the Working Alliance Inventory - Short Form (WAI-SF)
Time Frame: Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
The 12-item WAI-SF measures agreement on goals and tasks of therapy and the bond between the therapist and the client and has demonstrated good reliability and convergent validity.
Items are rated on a 5-point Likert scale with higher scores indicating a better therapeutic alliance.
The WAI-SF will be used to assess the patient-provider alliance.
|
Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
Person-centered care as measured by the Combined Assessment of Psychiatric Environments (CAPE)
Time Frame: Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
CAPE assesses patient perspective patient-centered care and shows internal consistency reliability, test-retest reliability, and construct and criterion validity.
|
Post-intervention (after 12th session or 6-months after start of intervention, whichever comes first)
|
|
Family involvement
Time Frame: Weekly per session up to 12 sessions, up to 6 months
|
Family involvement, or whether a family member was present at a service encounter, will be assessed by an independent observer based on review of service.
This method has been used in prior early intervention studies.
|
Weekly per session up to 12 sessions, up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Maria Santos, PhD, California State University, San Bernardino
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2022
Primary Completion (Actual)
December 16, 2025
Study Completion (Estimated)
June 30, 2026
Study Registration Dates
First Submitted
February 10, 2022
First Submitted That Met QC Criteria
March 26, 2022
First Posted (Actual)
April 5, 2022
Study Record Updates
Last Update Posted (Actual)
March 18, 2026
Last Update Submitted That Met QC Criteria
March 16, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-FY2020-167
- K23MH119313 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Engagement, Patient
-
Cedars-Sinai Medical CenterTerminated
-
University of AarhusUnknownPatient Engagement | Patient Empowerment | Patient Compliance
-
University of WashingtonNational Institute of Mental Health (NIMH); Mental Health America; TalkspaceCompleted
-
Inonu UniversityCompleted
-
The Cleveland ClinicActive, not recruitingPatient EngagementUnited States
-
University of North Carolina, Chapel HillCompleted
-
NYU Langone HealthCompleted
-
University of California, San DiegoPatient-Centered Outcomes Research Institute; University of Massachusetts,... and other collaboratorsCompletedPatient Engagement | Physician-Patient Relations | Physician's Role | Patient ActivationUnited States
-
Medical College of WisconsinCompletedCommunication | Patient EngagementUnited States
-
Palo Alto Medical FoundationUniversity of Rochester; Dartmouth College; Gordon and Betty Moore Foundation; ... and other collaboratorsCompletedPatient Engagement | Physician's Role | Physician-Patient Relationship
Clinical Trials on Behavioral Activation for First Episode Psychosis
-
Basque Health ServiceCompletedFirst-episode Psychosis | Cannabis AbuseSpain
-
Douglas Mental Health University InstituteCanadian Institutes of Health Research (CIHR)CompletedPsychosis | Social PhobiaCanada
-
Pakistan Institute of Living and LearningRecruitingIndividuals at Risk of First Episode PsychosisPakistan
-
University of MinnesotaUniversity of California, San FranciscoCompletedSchizophrenia | Schizoaffective Disorder | Psychosis | Psychosis NOS | Schizophreniform Disorders | Unspecified Psychosis | Bipolar Disorder With Psychotic Features | Depression Psychotic FeatureUnited States
-
Punjab Institute of Mental HealthCompletedPsychotic Disorders | Psychosis | Schizophrenia and Related DisordersPakistan
-
University of MichiganNational Institute of Mental Health (NIMH)Completed
-
Rigshospitalet, DenmarkLundbeck Foundation; Mental Health Services in the Capital Region, Denmark; Center...RecruitingCognitive Dysfunction | Depressive Disorder, Major | Cognitive Behavioral Therapy | Treatment Outcome | Antidepressive AgentsDenmark
-
Ciusss de L'Est de l'Île de MontréalCanadian Institutes of Health Research (CIHR)RecruitingTreatment-resistant Schizophrenia | Auditory Hallucination, VerbalCanada
-
Ciusss de L'Est de l'Île de MontréalOtsuka Canada Pharmaceutical Inc.CompletedTreatment-resistant Schizophrenia | Auditory Hallucination, VerbalCanada
-
The University of Texas Health Science Center,...Completed